Net loss per share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net loss per share

Net loss per share

The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect (in thousands):

	For the three months ended March 31,
	2024
Outstanding stock options(1)	7,903
Restricted stock units(1)	5,449
Warrants	2,586
ESPP shares and other	84
	16,022

(1) Outstanding stock options and restricted stock units include awards outstanding to employees of 2seventy bio.

Net loss per share for the three months ended March 31, 2024 was $0.36.

During the three months ended March 31, 2023, the Company had net income of $18.9 million. Basic weighted-average common shares outstanding were 102.9 million, the effect of dilutive securities was 0.4 million, and diluted weighted-average common shares outstanding were 103.3 million. Basic earnings per share and diluted earnings per share were both $0.18.